Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Apr 7 2010

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62^nd Annual Meeting to be held in Toronto, Canada.

Dawn McGuire, M.D., Chair of Opexa's Clinical Advisory Board and the Company's acting Chief Medical Officer, will present data from the Phase 2b TERMS clinical trial which demonstrated promising efficacy and safety data in patients treated with Tovaxin^®, the Company's lead therapy for MS.

The data will be presented during a poster session on Wednesday, April 14, 2010 from 6:00 to 7:30 p.m. at Poster Session P04, located at P04.211 in the poster hall under the following title: Safety and Efficacy of Autologous T-Cell Immunotherapy (Tovaxin) in Patients with Active Relapsing-Remitting Multiple Sclerosis.

Established in 1948, the American Academy of Neurology is an international professional association of more than 22,000 neurologists and neuroscience professionals. The 62^nd Annual Meeting will be held in Toronto, April 10 to April 17, 2010, and will highlight the latest in neurologic research through key lectures, over 2,300 poster and platform sessions, and 175 educational programs. More than 10,000 people are expected to attend the meeting this year.